Home  /  Resource Library  /  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3 year study results

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3 year study results

Results of a study investigating brentuximab vedotin combined with nivolumab for treatment of relapsed Hodgkin lymphoma. (Abstract only)